Prohibited concomitant medication
tumor, gastric cancer
TUMOR, GASTRIC CANCER
The following medications/treatments are not allowed during the study participation, unless the patient is in the follow-up phase and has permanently discontinued any study medication:Any investigational medicinal product or experimental therapy or participation in another clinical trial. Any other anti-tumor treatment including chemotherapy, targeted therapy, antibodies, any antihormonal tumor treatment, and immunotherapy other than FTD/TPI and Irinotecan.Current data in gastric cancer indicate a potential worse survival for patients receiving fluoropyrimidine-derivates with the concomitant use of protone-pump inhibitors, which should be avoided if possible. For details of contraindications, Investigators should refer to the respective SmPC. Caution is required when using medicinal products that are human thymidine kinase substrates, e.g., zidovudine. Such medicinal products, if used concomitantly with FTD/TPI, may compete with the effector, trifluridine, for activation via thymidine kinases. Therefore, when using antiviral medicinal products that are human thymidine kinase substrates, monitor for possible decreased efficacy of the antiviral medicinal product, and consider switching to an alternative antiviral medicinal product that is not a human thymidine kinase substrate, such as lamivudine, and abacavir. It is unknown whether FTD/TPI may reduce the effectiveness of hormonal contraceptives. Therefore, women using hormonal contraceptive must also use a barrier contraceptive method.